Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis by Gaebler JA, Soto-Campos G, Alperin P, Cohen M, Blickensderfer A, Wintle M, Maggs D, Hoogwerf B, Han J, Pencek R, Peskin B

Get full text

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. by Gerstein, H, Yusuf, S, Bosch, J, Pogue, J, Sheridan, P, Dinccag, N, Hanefeld, M, Hoogwerf, B, Laakso, M, Mohan, V, Shaw, J, Zinman, B, Holman, R